SPDL1 and cancer: Hence, this meta-analysis was conducted by pooling data from selected studies to evaluate the relationship between the value of sPD-L1 in the blood at baseline and the response to immunotherapy, both in terms of progression-free survival (PFS) and overall survival (OS), in cancer patients affected by solid tumors and treated exclusively with ICIs.